Clinical Trials Logo

Advanced Solid Neoplasm clinical trials

View clinical trials related to Advanced Solid Neoplasm.

Filter by:
  • None
  • Page 1

NCT ID: NCT03486314 Completed - Clinical trials for Advanced Solid Neoplasm

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

Start date: August 13, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.

NCT ID: NCT03330106 Completed - Clinical trials for Advanced Solid Neoplasm

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

Start date: November 15, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the effects of 25 and 50 milligram per square meter (mg/m^2) pevonedistat on the Fridericia corrected QT interval (QTcF) of the electrocardiogram (ECG).

NCT ID: NCT03061188 Active, not recruiting - Clinical trials for Refractory Mantle Cell Lymphoma

Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes

Start date: May 23, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to determine the highest and safest dose of the experimental drug veliparib when combined with nivolumab. We will also study how safely this combination of medication can be given in advanced cancer and lymphoma and benefits of receiving this therapy. Nivolumab is currently approved in certain cancers such as melanoma, lung cancer and kidney cancer. Veliparib is not yet approved for use in the United States, and is considered experimental. Veliparib inhibits (blocks) the activity of the enzyme PARP. This blocking activity may prevent the cancer cell from repairing itself and resume growing. Nivolumab increases T cells in your immune system, which allows your immune system to attack the cancer. We think the combination of these drugs will be more effective against your cancer.